Brandon H Pham1, Michael F Marmor2. 1. Stanford University School of Medicine, Stanford, California. 2. Byers Eye Institute at Stanford, Palo Alto, California.
Abstract
PURPOSE: To characterize the stability or progression of different stages of hydroxychloroquine (HCQ) retinopathy up to 20 years after stopping the drug. METHODS: We reviewed findings from 13 patients with initial HCQ retinopathy classified as early (patchy photoreceptor damage), moderate (ring of photoreceptor thinning or scotoma), or severe (retinal pigment epithelial [RPE] damage). Patients had been off HCQ for as many as 14 years at initial examination and were subsequently followed for 5 years to 8 years with repeated fundus autofluorescence and spectral domain optical coherence tomography. RESULTS: Early and moderate cases stabilized in fundus autofluorescence appearance, foveal thickness, ellipsoid zone line length, and visual acuity for up to 9 years after stopping HCQ. By contrast, severe cases demonstrated a continual loss of these parameters for up to 20 years off the drug. The presence of RPE damage at initial examination predicted progressive retinopathy over many years. CONCLUSION: The steady progression of severe HCQ retinopathy in eyes showing RPE damage after drug cessation suggests a metabolic insult that chronically destabilizes rather than destroys cellular function, with a clinical course resembling that of genetic dystrophies. Our findings stress the importance of early detection to minimize progression and visual loss.
PURPOSE: To characterize the stability or progression of different stages of hydroxychloroquine (HCQ) retinopathy up to 20 years after stopping the drug. METHODS: We reviewed findings from 13 patients with initial HCQ retinopathy classified as early (patchy photoreceptor damage), moderate (ring of photoreceptor thinning or scotoma), or severe (retinal pigment epithelial [RPE] damage). Patients had been off HCQ for as many as 14 years at initial examination and were subsequently followed for 5 years to 8 years with repeated fundus autofluorescence and spectral domain optical coherence tomography. RESULTS: Early and moderate cases stabilized in fundus autofluorescence appearance, foveal thickness, ellipsoid zone line length, and visual acuity for up to 9 years after stopping HCQ. By contrast, severe cases demonstrated a continual loss of these parameters for up to 20 years off the drug. The presence of RPE damage at initial examination predicted progressive retinopathy over many years. CONCLUSION: The steady progression of severe HCQ retinopathy in eyes showing RPE damage after drug cessation suggests a metabolic insult that chronically destabilizes rather than destroys cellular function, with a clinical course resembling that of genetic dystrophies. Our findings stress the importance of early detection to minimize progression and visual loss.
Authors: Rachel Shah; Joseph M Simonett; Riley J Lyons; Rajesh C Rao; Mark E Pennesi; Nieraj Jain Journal: JAMA Ophthalmol Date: 2020-08-01 Impact factor: 7.389
Authors: Vivienne C Greenstein; Jose Ronaldo Lima de Carvalho; Rait Parmann; Luz Amaro-Quireza; Winston Lee; Donald C Hood; Stephen H Tsang; Janet R Sparrow Journal: Invest Ophthalmol Vis Sci Date: 2020-09-01 Impact factor: 4.799
Authors: Kyle D Kovacs; Anton Orlin; Dolan Sondhi; Stephen M Kaminsky; Donald J D'Amico; Ronald G Crystal; Szilárd Kiss Journal: Transl Vis Sci Technol Date: 2021-07-01 Impact factor: 3.283